Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.
about
Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to FunctionThe Transcription Repressor REST in Adult Neurons: Physiology, Pathology, and Diseases(1,2,3)Autophagy in polyglutamine disease: Imposing order on disorder or contributing to the chaos?Therapeutic Targeting of AutophagyNADPH oxidase promotes Parkinsonian phenotypes by impairing autophagic flux in an mTORC1-independent fashion in a cellular model of Parkinson's diseaseRasd2 Modulates Prefronto-Striatal Phenotypes in Humans and 'Schizophrenia-Like Behaviors' in Mice.Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease.Mini-review: Retarding aging in murine genetic models of neurodegenerationGlycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat dietPIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In VivoModulation of mTOR signaling as a strategy for the treatment of Pompe disease.mTOR in Brain Physiology and Pathologies.Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer.Phosphatidylinositol 3 kinase (PI3K) modulates manganese homeostasis and manganese-induced cell signaling in a murine striatal cell line.PRAS40 alleviates neurotoxic prion peptide-induced apoptosis via mTOR-AKT signaling.The pathophysiology of defective proteostasis in the hypothalamus - from obesity to ageing.Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles.Transcriptome sequencing reveals aberrant alternative splicing in Huntington's disease.Neuronal mTORC1 Is Required for Maintaining the Nonreactive State of Astrocytes.Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.Towards an Understanding of Energy Impairment in Huntington's Disease Brain.Polyglutamine spinocerebellar ataxias - from genes to potential treatments.Striatal neurons directly converted from Huntington's disease patient fibroblasts recapitulate age-associated disease phenotypes.The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging.Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease.Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors.Cardiac mTORC1 Dysregulation Impacts Stress Adaptation and Survival in Huntington's Disease.The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders.RHEB1 insufficiency in aged male mice is associated with stress-induced seizures.Staufen1 links RNA stress granules and autophagy in a model of neurodegenerationmTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
P2860
Q26770762-67ED1F14-6C48-4E33-B80A-DF73433F3ED7Q26783252-DAF2CD1C-9B0D-4BCA-85B3-208AAE813C93Q27011387-B777DC07-2312-4AAC-B57E-63738EFFE041Q28078117-FE7409D4-5398-45B1-94F3-439AAC838A85Q28389251-29C96913-24AD-46B8-B909-700A276E24E4Q30364690-C7973F3D-5D65-4D5D-9FFE-7744D62E1009Q33831774-867D93D8-FA3E-46FA-83AC-2416F83682C4Q33914286-7234C536-E6D1-40F2-81C4-E27672FF07B0Q36396137-8C9B883F-A25F-4CA5-85D1-9812CA63ED32Q37014362-69D8AAC2-CBAC-4C00-8FB9-67D3427F2315Q37088539-F83A842A-6F3B-46D1-AC5C-8E1FB81ECC4CQ37672756-29F53472-FBC2-4431-A6B7-3B0DB09B7C91Q38565769-9302D0A7-3BE2-450E-8257-54D46C5F49C1Q38607849-8CB90BCA-646D-4223-956E-B83D82533FA6Q38655453-C913A875-FB6E-4B99-8C2F-DBF1E805F675Q38695652-9549C9F1-71B8-438D-B6E9-47ADA1829D06Q38712234-C169C72B-CBBF-4981-B83E-3F656ED1F60AQ38889413-573AEE34-8371-4403-BDAA-077E0F9CD389Q39321120-179EF251-2AEC-4887-8FD0-CD6EF561C64AQ39631653-E794593D-87E7-490B-AE50-69F1473741D5Q41921633-BAB7BE2E-0580-4B1A-9E7D-0DDCC0D26073Q45305901-23A29B95-5874-4D3F-BCF7-7D25B0479CB9Q47442924-977BF32A-F999-470C-8202-42B08BE646DDQ47880472-F67DB4C6-FC13-40EE-B705-D3906FCA4DDEQ48102811-EC33F01D-87FC-4545-90D3-D23FD9BB79E0Q48923348-97F804E4-A4BF-455E-9C64-2FA6217414F0Q51238345-ECAA4CCC-E8F8-4A16-98FD-52A5AE1C5235Q51761339-2519AFA4-E935-41FB-A2C5-8EB8D661F64BQ52309831-E72E0359-7045-42D8-BBF1-0B3AC1D60967Q52361076-C6F61111-B18D-43CE-A2AF-991CBC03DD3FQ54146954-51A4D96D-7FCF-433C-AE1B-5F907997A1E3Q58759815-5E81A2F2-A15D-436C-9B13-F8C6D621CA95Q58795101-AAFDE8DF-C0AF-4CEE-B7F0-422CBFF2A4DE
P2860
Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Reinstating aberrant mTORC1 ac ...... ce improves disease phenotypes
@nl
Reinstating aberrant mTORC1 ac ...... e improves disease phenotypes.
@ast
Reinstating aberrant mTORC1 ac ...... e improves disease phenotypes.
@en
type
label
Reinstating aberrant mTORC1 ac ...... ce improves disease phenotypes
@nl
Reinstating aberrant mTORC1 ac ...... e improves disease phenotypes.
@ast
Reinstating aberrant mTORC1 ac ...... e improves disease phenotypes.
@en
prefLabel
Reinstating aberrant mTORC1 ac ...... ce improves disease phenotypes
@nl
Reinstating aberrant mTORC1 ac ...... e improves disease phenotypes.
@ast
Reinstating aberrant mTORC1 ac ...... e improves disease phenotypes.
@en
P2093
P2860
P1433
P1476
Reinstating aberrant mTORC1 ac ...... e improves disease phenotypes.
@en
P2093
Alex Mas Monteys
Beverly L Davidson
John H Lee
Leslie M Thompson
Luis Tecedor
Matthew J Sowada
Yong Hong Chen
P2860
P304
P356
10.1016/J.NEURON.2014.12.019
P407
P577
2014-12-31T00:00:00Z